Merck, OMT announce new antibody discovery collaboration

Published on July 9, 2012 at 7:38 AM · No Comments

Open Monoclonal Technology, Inc. (OMT) today announced an antibody discovery collaboration with Merck KGaA. OMT and Merck KGaA have entered into a collaboration whereby OMT will use its OmniRats™ to generate antibodies against several targets selected by Merck KGaA. Merck KGaA has the rights to further develop and commercialize the antibodies derived from the OmniRat™ as therapeutic and diagnostic products. Under the terms of the agreement, OMT will receive upfront payment, success-based milestones, and royalties.

"We are pleased to be collaborating with Merck KGaA. OMT's OmniRat™ generates antibodies with great specificity, affinity and manufacturability. Our partners are looking for technologies that can eliminate time-consuming humanization of antibodies or optimization of leads identified using display technology. The OmniRat™ can save significant development time and is available for all targets", said Roland Buelow, Founder and CEO of OMT.

Source:

Open Monoclonal Technology, Inc.    

Posted in: Device / Technology News | Medical Science News

Tags: , , , ,

Read in | English | Español | Français | Deutsch | Português | Italiano | 日本語 | 한국어 | 简体中文 | 繁體中文 | Nederlands | Русский | Svenska | Polski
Comments
The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
MedImmune initiates MEDI8897 phase I clinical studies for treatment of RSV infections